Evidence map›Paper›PMID 38927381›Full record

ArticleBiomedicines2024

Impact of Inherited Thrombophilia in Women with Obstetric Antiphospholipid Syndrome: A Single-Center Study and Literature Review.

Blanca Camacho Sáez, Víctor M Martínez-Taboada, Ana Merino, Alejandra Comins-Boo, Belén González-Mesones, Sara Del Barrio-Longarela, Leyre Riancho-Zarrabeitia, Marcos López-Hoyos, José L Hernández

Abstract read
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Blanca Camacho SáezDivision of Rheumatology, Hospital Marqués de Valdecilla-IDIVAL, 39008 Santander, Spain.
Víctor M Martínez-TaboadaDivision of Rheumatology, Hospital Marqués de Valdecilla-IDIVAL, 39008 Santander, Spain.ORCID 0000-0003-2916-8491
Ana MerinoDivision of Obstetrics and Gynecology, Hospital Marqués de Valdecilla, 39008 Santander, Spain.
Alejandra Comins-BooImmunology Department, Hospital Universitario Marqués de Valdecilla-IDIVAL, 39008 Santander, Spain.ORCID 0000-0001-8353-6211
Belén González-MesonesHeamatology Department, Hospital Universitario Marqués de Valdecilla-IDIVAL, 39008 Santander, Spain.
Sara Del Barrio-LongarelaDivision of Obstetrics and Gynecology, Hospital Marqués de Valdecilla, 39008 Santander, Spain.
Leyre Riancho-ZarrabeitiaRheumatology Department, Hospital Sierrallana-IDIVAL, 39300 Torrelavega, Spain.
Marcos López-HoyosImmunology Department, Hospital Universitario Marqués de Valdecilla-IDIVAL, 39008 Santander, Spain.ORCID 0000-0003-0562-427X
José L HernándezDepartamento de Medicina y Psiquiatría, Universidad de Cantabria, 39011 Santander, Spain.ORCID 0000-0002-6585-8847

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inherited thrombophilia (IT) has been implicated as a potential causal factor of adverse pregnancy outcomes (APOs), including recurrent miscarriage with and without the presence of antiphospholipid syndrome (APS). The aim of this study was to assess the prevalence and impact of IT on fetal-maternal outcomes and thrombotic risk in women within the spectrum of obstetric APS. Three hundred and twenty-eight women with APS-related obstetric morbidity ever pregnant were included. Of these, 74 met the APS classification criteria, 169 were non-criteria (NC)-APS, and 85 were seronegative (SN)-APS. Patients with other autoimmune diseases were excluded. APOs included early pregnancy loss, fetal death, preeclampsia, abruptio placentae, and preterm birth. Successful pregnancy was defined as the achievement of a live newborn. A literature search was also performed. The mean age of the overall group was 33.9 ± 5.3 years, and the patients were followed up for 35 (11-79) months. During the study period, there were 1332 pregnancies. Nearly 14% of the patients had an associated IT. IT patients more frequently received the standard-of-care (SoC) therapy. The presence of IT was not associated with worse maternal-fetal outcomes in patients treated with SoC treatment. Overall, IT patients had a lower frequency of newborns without treatment, especially those without definite APS. In addition, IT did not increase the risk of thrombosis during pregnancy or the postpartum period. A detailed analysis of the literature review identified only four publications related to our study and did not show conclusive evidence of the impact of IT on patients with obstetric APS. The group of women with APS-related obstetric morbidity and IT who did not receive treatment, especially those without definite APS, had a worse prognosis in terms of a live birth. However, with SoC therapy, the prognosis is similar in those patients without IT. The association of IT with APS does not seem to predispose to the development of thrombosis during pregnancy and/or the postpartum period.

Indexed as

antiphospholipid antibodiesantiphospholipid syndromefetal lossinherited thrombophiliaobstetric morbiditypregnancy

Identifiers

PMID38927381
PMCPMC11201097

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.